Contribute Try STAT+ Today
Trending:
Coronavirus
Biotech
Health
First Opinion

STAT+ Latest

Columns: Adam’s TakePharmalot

Topics: BiotechPharmaPolicyHealth TechBusiness

Features: STAT+ Conversations CRISPR TrackrDrug Pricing Policy TrackerWebinars

Events: See upcoming events

white pill/blk background
Biotech

Ovid’s treatment for a rare, untreatable disease fails in a key trial

By Damian Garde

Pharma

STAT+ Conversations: A conversation on drug pricing, policy, and access

By Ed Silverman

Pharma

Pharmalittle: Serum Institute threatens to sue Covid-19 vaccine trial participant; U.S. agency prepares for Covid-19 vaccine fraud

By Ed Silverman

Biotech

Agios drug for rare form of anemia achieves main goal of late-stage clinical trial

By Adam Feuerstein

STAT China

Legend Biotech believes it is not a target of Chinese investigation, CEO says

By Jonathan Chan

Sen. Richard Burr
Politics

Burr, in line to lead Senate Republicans’ health strategy, has a long history of antagonizing the FDA

By Nicholas Florko

HHS 2020
Pharma

HHS spikes a drug approval program that inadvertently led to price hikes and shortages

By Ed Silverman

HIV-1
Pharmalot

Medicines Patent Pool expands deal for access to key HIV drug to several upper middle-income countries

By Ed Silverman

Pharmalot

Pharmalittle: Moderna seeking regulatory clearance for Covid-19 vaccine; charter flights begin for Pfizer vaccine

By Ed Silverman

STAT SPOTLIGHT
Biotech

Startup Spotlight: Bullish on its asthma treatment, Kinaset forges ahead in unusual times

By Kate Sheridan

Pieter van Hengel/Kite Pharma
Biotech

‘How are we going to get on that plane?’: The transatlantic race to deliver CAR-T cancer therapy during the pandemic

By Eric Boodman

Sad child
Biotech

In major bet, Biogen pays $1.5 billion for rights to a once-failed treatment for depression

By Damian Garde and Adam Feuerstein

Purdue in the weeds
Pharmalot

House committee wants Purdue CEO and Sackler family members to testify at opioid crisis hearing

By Ed Silverman

Pharmalittle: Purdue pleads guilty to opioid charges; Chinese firm files for Covid-19 vaccine approval

By Damian Garde

telehealth clinical trial
Health Tech

‘The trend is irreversible’: How Covid-19 could drive a shift toward decentralized trials

By Casey Ross

FDA through the window
Biotech

Alnylam wins FDA approval for first drug to treat rare kidney disease

By Anissa Gardizy — Boston Globe

D.C. Insight IMAGE
Politics

Which pricey drugs will Trump’s international pricing policy target?

By Nicholas Florko

Pharmalot

Pharmalittle: EU plots a crackdown on delay of generic drugs; Russia says its Covid-19 vaccine is 95% effective

By Damian Garde

Catamaran
Biotech

A new startup wants to use natural killer cells to fight cancer

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: AstraZeneca says its vaccine cuts Covid-19 risk by 70%; U.S. shots will ‘hopefully’ start within three weeks

By Elizabeth Cooney

Merck logo
Biotech

Merck to pay $425M for biotech to get Covid-19 drug, but says manufacturing will be a challenge

By Matthew Herper

Robert Nelsen
Exclusive

Raging at the pandemic, a VC raises $800M for a company that aims to transform biotech manufacturing

By Matthew Herper and Damian Garde

Drug pricing
Pharmalot

NIH fails to disclose enough details about drug licensing, watchdog report finds

By Ed Silverman

11/ 20 D Trump
Politics

Trump’s making last-minute drug pricing reforms — and surprisingly, Democrats want Biden to keep the biggest one

By Nicholas Florko and Lev Facher

Human B Lymphocyte
In the Lab

New research underscores the link between multiple sclerosis and the gut microbiome

By Kate Sheridan

Hires -- up and down the ladder
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer asking today for emergency-use status for Covid-19 vaccine; Trump to release drug-pricing rules

By Ed Silverman

Metastatic Melanoma Cells
In the Lab

Cancer vaccine cocktail boosts immune response after melanoma surgery, research shows

By Elizabeth Cooney

Oxycontin
Pharmalot

To maintain opioid sales, Purdue was advised to pay rebates to health insurers for each overdose

By Ed Silverman